Advertisement

Topics

Latest "Cell Signaling Technologies" News Stories

12:59 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Cell Signaling Technologies" found in our extensive news archives from over 250 global news sources.

More Information about Cell Signaling Technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cell Signaling Technologies for you to read. Along with our medical data and news we also list Cell Signaling Technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cell Signaling Technologies Companies for you to search.

Showing "Cell Signaling Technologies" News Articles 1–25 of 12,000+

Thursday 21st February 2019

City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer Institute

The coveted grant of $12.5 million recognizes new and diverse approaches to lymphoma prevention, detection, diagnosis and treatment An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third


Shift4 Payments to Sponsor St. Jude Charity Poker Tournament

The Annual “Against All Odds” Charity Event Raises Money to Pay for Treatment of Children Diagnosed With Cancer LAS VEGAS (PRWEB) February 21, 2019 Shift4 Payments, the leader in secure payment processing solutions, announced that they will be sponsors of the upcoming St. Jude Against All Odds Poker Tournament. The charity event will take place on Saturday, March 2, 2019, at the Red Rock Casi...

Mauna Kea Technologies Provides an Update on Its Commercial Partnership Agreement for Urological Applications

Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a mutual decision to terminate the development and distribution agreements with Cook Medical. “Mauna Kea an...


Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries http://bit.ly/2S7XTt6  #iPS細胞 #stemcells #pharmapic.twitter.com/XyEyfz3g5E

Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries http://bit.ly/2S7XTt6  #iPS細胞 #stemcells #pharma pic.twitter.com/XyEyfz3g5E

Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling

ATS harnesses electromagnetic technology for cell minimizing unit

ATSâ SuperTrak Micro minimizes cell sizes through electromagnetic sorting while merging and diverting at full production speed.

Hoopes Vision Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

Phillip C. Hoopes, Jr., M.D. and Majid Moshirfar, M.D. at Hoopes Vision in Draper, Utah, are participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts. “As a clinical study site, we at Hoopes Vision are able to give our patients access to the most cutting-edge treatment options for ...

Community pharmacy vital to deploying 'Big Data' and artificial intelligence in practice, says PGEU

The Pharmaceutical Group of the European Union says community pharmacy could use new technologies to dedicate more working time to providing patient care, use patient data to provide a more personalised healthcare service and utilise mobile health tools to identify at-risk patients.

MorphoSys to Present at Upcoming Investor Conference

DGAP-News: MorphoSys AG / Key word(s): Conference 21.02.2019 / 14:00 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, February 21, 2019 MorphoSys to Present at Upcoming Investor Conference MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference:   8th Annual Leerink ...

Ben Bulkley Named Chief Executive Officer of EnvisionRxOptions

Rite Aid announced today that Ben Bulkley, an established executive with more than 20 years’ experience in health care and technology, has been named chief executive officer of EnvisionRxOptions, a pharmacy benefit management (PBM) company and wholly owned subsidiary of Rite Aid. Bulkley will report to Rite Aid CEO John Standley. Bulkley was mos...

Leafbuyer Technologies, Inc. Announces Total Network Traffic Increase

Growth to Nearly 10 Million Cannabis Consumers Per Month Leafbuyer Technologies, Inc. (LBUY) (“Leafbuyer” or “the Company”), announced today its Total Network traffic reached 9.85 million impressions in January 2019. This increase reflects 25.48% growth recorded during the month versus the same month the previous year. “We dev...

Salt Implicated in Allergic Immune Reactions

  Researchers led by Christina Zielinski, MD, a professor at the Institute for Virology at the Technical University of Munich (TUM), say they have demonstrated in cell cultures that salt leads to the formation of Th2 cells, which are active in allergic conditions such as atopic dermatitis. The team also detected elevated salt concentrations in the skin […] The post Salt Implicated in ...

Dietary Salt Mediates Allergic Diseases

Researchers at the Institute for Virology at the Technical University of Munich (TUM), say they have demonstrated in cell cultures that salt leads to the formation of Th2 cells, which are active in allergic conditions such as atopic dermatitis. The team also detected elevated salt concentrations in the skin of patients. The post Dietary Salt Mediates Allergic Diseases appeared first on GEN - Genet...

Spacelabs Healthcare Receives $8 Million Order for Monitoring and Telemetry Upgrade Project

Spacelabs Healthcare (“Spacelabs” or the “Company”) today announced that it has been selected to complete a whole-house replacement of patient monitoring and telemetry equipment at a Level I Trauma Center in the western U.S. The project spans 43 departments and includes Spacelabs’ central stations, high-acuity bedside and transport monitors, as well as ...

Ibrutinib/Palbociclib Combo Shows Activity in Previously Treated MCL

Combining ibrutinib with the CDK4/6 inhibitor palbociclib appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma.

More than 30% of patients who are #CMV seropositive reactivate within 30 days of stem cell transplant #TCTM2019 #HSCTpic.twitter.com/XxiVysbVSK

More than 30% of patients who are #CMV seropositive reactivate within 30 days of stem cell transplant #TCTM2019 #HSCT pic.twitter.com/XxiVysbVSK

Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant

-- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standard of care G-CSF -- -- Cells mobilized with MGTA-145 plus plerixafor rapidly engrafted in non-human primates following autologous transplant -- -- MGTA-145-mobilized cells from non-human p...

Carol J. Burt Joins IQVIA Board of Directors

IQVIA™ (NYSE:IQV) today announced the appointment of Carol J. Burt to its board of directors, effective today. A principal of private investment firm Burt-Hilliard Investments for more than a decade, Burt is a former executive officer of WellPoint, Inc. (now Anthem, Inc.), lastly as Senior Vice President, Corporate Finance and Development, and previ...

Citi Appointed as Depositary Bank for Stealth BioTherapeutics’ ADR Programme

Citi, acting through Citibank N.A., has been appointed by Stealth BioTherapeutics Corp. (“Stealth”) as depositary bank for its American Depositary Receipt (“ADR”) programme. Stealth’s ADRs trade on the Nasdaq Global Market under the symbol “MITO.” Each ADR represents 12 ordinary shares of Stealth. “We are pleased to have been selec...

ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City. The...

ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be acc...

Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the publication of findings that further elucidate the regulatory arm of the novel mechanism of action for BT-11, its investigational new

ReNeuron's Cell Therapy Garners Excitement In RP-Related Vision Loss

A surprisingly strong improvement in vision has accompanied the use of proprietary stem cells in the first three retinitis pigmentosa...   

Biomed specialist appoints WHP to deliver expansion project

Gene and cell therapy Oxford BioMedica have appointed a multi-disciplinary engineering company to help expand its bioprocessing operations and manufacturing capabilities.

Merck to Acquire Immune Design

Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per sh...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks